prikaz prve stranice dokumenta Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
  Download
PDF 895.43 KB
Scientific paper - Original scientific paper
Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
Journal of Personalized Medicine, 14 (2024), 3; 278. https://doi.org/10.3390/jpm14030278
Vučinić, Damir; Skočilić, Iva; Golčić, Marin; Dobrila-Dintinjana, Renata; Kolak, Maja; Jerković, Ivona; Tesar, Eleonora Cini; Ferari, Ani Mihaljević; Ređović, Arnela; Marušić, Jasna; Kolovrat, Doris; Mikolašević, Ivana

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Vučinić, D., Skočilić, I., Golčić, M., Dobrila Dintinjana, R., Kolak, M., Jerković, I. ... Mikolašević, I. (2024). Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients. Journal of Personalized Medicine, 14. (3). doi: 10.3390/jpm14030278

Vučinić, Damir, et al. "Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients." Journal of Personalized Medicine, vol. 14, no. 3, 2024. https://doi.org/10.3390/jpm14030278

Vučinić, Damir, Iva Skočilić, Marin Golčić, Renata Dobrila Dintinjana, Maja Kolak, Ivona Jerković, Eleonora Cini Tesar, et al. "Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients." Journal of Personalized Medicine 14, no. 3 (2024). https://doi.org/10.3390/jpm14030278

Vučinić, D., et al. (2024) 'Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients', Journal of Personalized Medicine, 14(3). doi: 10.3390/jpm14030278

Vučinić D, Skočilić I, Golčić M, Dobrila Dintinjana R, Kolak M, Jerković I, and sur.. Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients. Journal of Personalized Medicine [Internet]. 2024 March 01 [cited 2024 May 17];14(3). doi: 10.3390/jpm14030278

D. Vučinić, et al., "Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients", Journal of Personalized Medicine, vol. 14, no. 3, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:957807. [Accessed: 17 May 2024]

Metadata
Title (english)Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
AuthorDamir Vučinić https://orcid.org/0000-0002-5804-0799
AuthorIva Skočilić
AuthorMarin Golčić
AuthorRenata Dobrila-Dintinjana
AuthorMaja Kolak
AuthorIvona Jerković
AuthorEleonora Cini Tesar
AuthorAni Mihaljević Ferari
AuthorArnela Ređović
AuthorJasna Marušić
AuthorDoris Kolovrat
AuthorIvana Mikolašević
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Background: The development of immunotherapy checkpoint inhibitors (ICIs) has revolutionized cancer care. However, old patients are underrepresented in most clinical trials, although they represent a significant proportion of real-world patients. We aimed to evaluate the effectiveness and safety of ICIs in patients older than the age of 70. Methods: We performed a retrospective chart review of 145 patients aged 70 or older treated with ICIs for metastatic or unresectable cancer. Results: Median progression-free survival (PFS) was 10.4 months (95% CI 8.6–13.7), with no differences between octogenarians and septuagenarians (p = 0.41). Female gender (p = 0.04) and first-line treatment setting (p < 0.0001) were associated with a longer median PFS. Median overall survival (OS) was 20.7 months (95% CI 13.5–35.0 months), with no difference based on performance status, cancer site, gender, or between septuagenarians and octogenarians (all p > 0.005). Patients treated with ICIs in the first-line setting reported longer OS compared to treatment in the second-line setting (p < 0.001). Discontinuation of ICIs due to adverse effects was associated with both shorter PFS (p = 0.0005) and OS (p < 0.0001). Conclusion: The effectiveness of ICIs in older cancer patients primarily depends on the line of treatment and treatment discontinuation. Octogenarians experienced similar treatment responses, PFS, OS, and adverse effects compared to septuagenarians.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleJournal of Personalized Medicine
Numberingvol. 14, no. 3, 278
e-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm14030278
URN:NBNurn:nbn:hr:184:957807
Publication2024-03-01
Document URLhttps://www.mdpi.com/2075-4426/14/3/278
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-03-05 08:45:56